At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 189 enrolled
Drug / intervention
degarelixdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomised, Multi-centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months
In Brief
A Phase 2 clinical trial evaluating degarelix for Prostate Cancer. Completed, enrolled 189 participants across 39 sites in 8 countries.
Detailed Summary
The purpose of the trial was to evaluate the safety and efficacy of degarelix when comparing six different doses. The patients participating in the trial were treated with degarelix every month for a year. During the treatment the patients had to visit the clinic for investigations. Blood samples for testosterone, dihydrotestosterone, luteinizing hormone, follicle stimulating hormone, and Prostate Specific Antigen were taken and analysed throughout the trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesBelgium, Germany, Hungary, Netherlands, Poland, Romania, Russia, South Africa
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
Primary CompletionJun 2005
Study CompletionSep 2005
First PostedJan 2009
TodayJul 2026
First PostedJan 8, 2009
Enrollment StartFeb 1, 2004
Primary CompletionJun 1, 2005
Study CompletionSep 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.5 years ago
Interventions
degarelixdrug
Degarelix was given as subcutaneous injections.